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Abstract 
Background: Acoustic neuromas are a common 
sequela of neurofibromatosis type 2 and have 
been shown to grow at an increased rate during 
pregnancy. 
Case: 21-year-old female, gravida 1 para 0, with 
history of neurofibromatosis type 2 presented for 
prenatal care following new onset seizures and 
progressive deafness. She was found to have 
bilateral slow-growing acoustic neuromas. Over 
the course of her pregnancy, her acoustic 
neuroma began growing and she became 
completely deaf. She underwent surgical 
decompression during her pregnancy and had a 
late preterm vaginal delivery due to 
preeclampsia with severe features. She 
subsequently had further operative and medical 
treatment of her neuromas. 
Conclusion: Acoustic neuromas during 
pregnancy are exceedingly rare, but can be 
managed successfully with an interdisciplinary 
team approach tailored to the patients’ specific 
clinical presentation. 
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Introduction 
Vestibular schwannomas are 
noncancerous tumors that grow on the 
eighth cranial nerve and are commonly 
seen in patients with neurofibromatosis 
type 2, an autosomal dominant genetic 
disease. The average age of symptom 
onset is 18 to 24 years and almost all 
affected individuals develop bilateral 
vestibular schwannomas by age 30 
years.1 Common features include 
tinnitus, hearing loss, balance 
dysfunction, as well as Bell’s palsy if 
there is  significant compression of the 
facial nerve.2 There is evidence showing 
that pregnancy hastens the progression 
of vestibular Schwannomas, but 
literature and practice guidelines are 
lacking  for the management  during 
pregnancy.2 This report describes such 
a rare case of vestibular schwannoma 
and the multidisciplinary management of 
its growth during pregnancy. 
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Case Presentation 
A 21-year-old woman, gravida 1 para 0, 
with an established history of 
neurofibromatosis type 2 (NF2) with an 
associated seizure disorder presented 
for prenatal care with the high-risk 
obstetrics group at our institution in 
2017.  In 2012 the patient was officially 
diagnosed with NF2 after  a syncopal 
episode prompted head imaging which 
revealed multiple tumors including a 
large meningioma and bilateral acoustic 
neuromas.  
 
 
Figure1. Axial T1 post-gadolinium contrast MRI of orbit depicting preoperative 
right cavernous sinus meningioma with involvement of right trigeminal nerve 
schwannoma 
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The patient underwent removal of the 
meningioma in October 2012 and 
resection of the larger right-sided 
acoustic neuroma in January 2013 with 
post-operative sequelae of partial right-
sided facial paralysis.   Within one 
month following the acoustic neuroma 
resection, her family relocated to Iowa 
and she was transferred to our 
institution. She presented to 
Ophthalmology with complaints of 
progressive vision loss and an orbit MRI 
showed right cavernous sinus 
meningioma (0.9 x 2.5 x 1.6 cm) with 
normal orbits, globes, and optic nerves, 
a slight increase in size of left-sided 
acoustic neuroma, and a right trigeminal 
schwannoma (Figure 1).  
 
 
Figure 2: Axial T1 post-gadolinium contrast MRI of postoperative brain depicting 
significant debulking of tumor with residual soft tissue mass adjacent to right 
cavernous sinus. 
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In April 2013, neurosurgery and ENT 
jointly resected the trigeminal 
schwannoma which was found to be 
emanating from V3 portion of the fifth 
cranial nerve. Immediate postoperative 
imaging revealed significant debulking 
with small soft tissue mass adjacent to 
right cavernous sinus concerning for 
residual tumor (Figure 2). At this time, 
she was also noted to have multiple 
small bilateral schwannomas along C5-
C7, T1, T2, L2-L5, S1 and S2 nerve 
roots. At 5 months follow-up she had 
persistent paresthesia in V2 and V3 
distribution with continued decline in 
hearing. She continued follow-up with 
ENT with MRI and audiograms every 3 
months to monitor tumor growth and 
hearing loss. She had significant 
sensorineural hearing loss in her right 
ear (which was not tested by audiogram 
regularly for this reason), however her 
left ear was showing progressive decline 
on audiograms. In March 2014, due to 
worsening hearing in the left ear (both 
subjective and objective decline in word 
recognition from 88% to 68% over two 
weeks), she was started on 
Bevacizumab therapy which resulted in 
symptomatic improvement. 
She initially presented to our obstetrics 
department for high-risk assessment 
and preconception counseling in June 
2017.  She was given extensive counsel 
regarding the probability of an increase 
in tumor size and the development of 
new tumors during pregnancy. She was 
also alerted to the risk of losing her 
vision or hearing permanently.  Since 
her tumor resection in 2013, regular MR 
imaging was done and her pre-
pregnancy tumor burden included 
bilateral trigeminal and vestibular 
schwannomas and right frontal 
meningioma, all stable over the prior 3 
years. In addition, she underwent 
genetic counseling at which time she 
was informed that the risk of her 
offspring inheriting the mutation is 50%.  
She decided to pursue fertility and 
presented at 7 weeks gestation with a 
planned and viable intrauterine 
pregnancy that was discovered during 
hospitalization for her first seizure in 
October 2017. Workup at that time 
found some epileptiform activity which 
was interpreted as likely secondary to 
her prior brain surgeries and she was 
discharged with levetiracetam 500 mg 
BID She declined any prenatal 
screening.  
 Over the course of the pregnancy, the 
patient was followed closely by 
otolaryngology (ENT) in addition to the 
high-risk obstetrics (MFM) team at our 
institution. As ENT had been monitoring 
her at regular 3-month intervals with 
audiograms and brain MRI since 2013, 
they continued the same protocol. Brain 
MRI at 9w6d showed grossly stable 
bilateral vestibular schwannomas, right 
frontal meningioma, and bilateral 
trigeminal schwannomas in comparison 
to the pre-pregnancy MRI three months 
prior. Her hearing progressively declined 
clinically over the course of pregnancy 
with intermittent episodes of blurred 
vision that were self-resolving and first 
reported at her 20wk appointment. 
Repeat MRI at 22 weeks’ gestation, 
roughly three months after her last MRI, 
demonstrated significant growth of the 
right vestibular schwannoma (increased 
to 4.0 x 2.4 cm from 2.7 x 1.7 cm) now 
resulting in brainstem compression. 
Audiogram done at this time showed 
0%-word recognition score (WRS) in 
patient’s left ear compared with 68% 10 
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months earlier. Given contraindications 
for the use of bevacizumab during 
pregnancy, a two-week course of 60 mg 
of prednisone daily was started to 
symptomatically improve hearing. 
However, this was unsuccessful, and 
the patient’s hearing continued to 
deteriorate.  An emergency room MRI 
was completed at 25 weeks for 
worsening symptoms including 
headaches, vomiting, taste changes and 
difficulty swallowing. This revealed 
stable schwannoma size with vasogenic 
edema in cerebellar hemispheres and 
vermis. Given the fact that the patient 
was at 25 weeks, delivery was not seen 
as a suitable option.   
A multidisciplinary case conference was 
set up and consensus opinion of 
participating consultants (ENT, 
neurosurgery, MFM, and anesthesia) 
was to proceed with surgical 
decompression of the brainstem with a 
goal to allow the patient to advance to 
term delivery. Fetal nonstress tests were 
conducted pre- and post-operatively 
without any intraoperative fetal 
monitoring as maternal hemodynamic 
stability was felt to be an adequate 
reflection of fetal wellbeing. The patient 
underwent successful resection of the 
right vestibular schwannoma at 26w2d 
gestational age.  The surgery was 
completed by both ENT and 
neurosurgery in the left-lateral tilt 
position under general endotracheal 
anesthesia with a translabrinth 
approach.  She had a two-day 
neurosurgical ICU stay for maternal 
neurological monitoring. She showed 
appropriate postoperative recovery and 
was discharged on postoperative day 3.  
After surgical intervention, the majority 
of her symptoms improved, except her 
hearing loss. 
The patient’s pregnancy was further 
complicated by preeclampsia with 
severe features due to severe range 
blood pressures that developed at 30 
weeks’ gestation. She was admitted at 
that time and remained hospitalized until 
delivery at 34 weeks.  Due to known 
spinal tumors, she was unable to 
undergo epidural anesthesia and opted 
therefore for vaginal delivery with 
fentanyl PCA for pain control. She was 
induced at 34 weeks and went through 
vaginal delivery without complications.  
Her clinical course was further 
complicated by postpartum 
preeclampsia for which she was treated 
with labetalol. She was discharged on 
hospital day 2. Her baby boy was born 
with APGARs of 2 and 5 at 1 and 5 
minutes and was admitted to the NICU 
due to respiratory distress and 
prematurity. He made appropriate 
improvements and was fit for discharge 
by day of life 26. Outpatient follow-up 
with pediatric genetics was arranged for 
testing and monitoring of the infant for 
NF2.  
Our patient followed up with ENT and 
neurosurgery 7 weeks post-partum for 
further assessment of her tumor growth.  
At that time, a plan was made to pursue 
cochlear implantation (CI) followed by 
resection of the left acoustic 
schwannoma so that if meaningful 
hearing was retained, a selective 
debulking of her tumor could be done. If 
there was no meaningful hearing 
retained, CI could be removed and the 
tumor fully resected. She underwent 
cochlear implantation approximately two 
months postpartum and noted 
improvement in hearing subjectively. 
Finally, at 4 months postpartum, she 
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underwent tumor debulking with a 
retrosigmoid approach and 
electrocorticographic monitoring with 
80% successful tumor debulking. This 
was completed with an interdisciplinary 
team composed of otolaryngologic and 
neurosurgical specialists. 
Discussion and review of the 
literature 
Neurofibromatosis Type 2 (NF2) is 
characterized by noncancerous tumors 
of the nervous system, and commonly 
present with vestibular schwannomas 
that develop along the auditory nerve. 
NF2 is inherited in an autosomal 
dominant pattern though approximately 
50% of individuals with NF2 have a de 
novo variant.3 Vestibular schwannomas 
present with symptoms of tinnitus, 
hearing loss, and balance dysfunction. 
Schwannomas may also develop in 
other peripheral nerves and affected 
individuals may also develop 
meningiomas, ependymomas and, 
rarely, astrocytomas.3 The average age 
of onset of symptoms in afflicted 
individuals ranges from 18 to 24 years 
and almost all affected individuals 
develop bilateral vestibular 
schwannomas by age 30 years. 
Diagnosis of NF2 in the pediatric 
population is often delayed due to a 
rather non-specific presentation; 
children often present with 
dermatological and ocular signs rather 
than with hearing loss.1 In this case, our 
patient presented classically in her 
teenage years with vestibular 
schwannomas as well as meningiomas 
and other scattered neuromas. 
There is some evidence showing that 
pregnancy accelerates clinical 
progression and radiographic growth of 
neuromas in NF2, as seen in our 
patient.2 One study of 103 patients 
showed that vestibular schwannomas 
occur more frequently in women and 
tend to be larger and more vascular in 
females.4 Two leading hypotheses 
regarding the mechanism of tumor 
growth during pregnancy consider the 
role of increased hormone receptors 
and increased blood volume during 
pregnancy.5 Several studies have 
investigated the expression of estrogen 
receptors in vestibular schwannoma. 
Brown et al. found an upregulation in 
estrogen receptors in sporadic 
vestibular schwannoma specimens 
compared with normal nerve samples in 
sixteen patients.6 This study directly 
contradicts findings by Beatty et al., who 
found no statistically significant 
association between the presence or 
quantity of estrogen or progesterone 
receptors in pregnancy and in 
progression of vestibular 
schwannomas.7  Multiple studies have 
shown that these tumors are large and 
more vascular during pregnancy and 
some contain estrogen receptors.8  
The management of acoustic neuromas 
in pregnancy depends on the stage of 
pregnancy and the location and size of 
the tumors. Maternal benefits must be 
weighed against fetal risk of harm when 
deciding on management strategies. 
Surgical resection of tumors is 
considered safe during the second 
trimester of pregnancy.8 A retrospective 
cohort study of nine women with a skull 
base tumor during pregnancy 
demonstrated successful emergent skull 
base surgery in the second trimester.9 
First trimester surgery carries an 
increased risk of spontaneous abortion, 
while third trimester surgery carries an 
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increased risk for preterm delivery.9 Our 
patient underwent tumor resection 
during late second trimester due to 
worsening symptoms. Given that she 
was not experiencing symptoms from 
her spinal tumors and other intracranial 
tumors, those were deferred to 
postpartum management. 
Acoustic neuromas presenting without 
evolving neurological deficit  can be 
managed  via close observation and 
treatment can be deferred to the 
postpartum period.2 Some patients with 
acoustic neuromas might experience 
hearing loss during pregnancy due to 
growth of the tumors.10 
Medical treatment has become available 
recently by employing targeted 
therapies such as Bevacizumab, a 
recombinant monoclonal antibody which 
inhibits vascular endothelial growth 
factor (VEGF). Bevacizumab has been 
shown to result in radiographically 
reduced tumor size and to delay hearing 
loss in patients with vestibular 
schwannomas.11 However, 
Bevacizumab is an IgG antibody and 
crosses the placenta.  Due to lack of 
sufficient information with respect to its 
use during pregnancy, the team opted to 
proceed with caution and discontinue 
this treatment during this patient’s 
pregnancy. In anticipation of the effects 
caused by withholding her Bevacizumab 
during pregnancy, the patient had been 
counseled with respect to the likelihood 
of tumor growth and prepared her for a 
possibility of further vision and hearing 
loss possibly necessitating surgical 
resection. 
Another important consideration when 
managing a pregnant patient with NF2 
and acoustic schwannomas is the need 
for an interdisciplinary approach to care. 
Complicated cases with tumor 
progression at a rate which causes 
worsening symptoms, require close 
communication and cooperation among 
ENT, neurosurgery, maternal-fetal 
medicine, anesthesiology, genetics, and 
social work in order to achieve the best 
possible outcomes.12 Lastly, the mode 
of delivery depends on the intracranial 
pressure (ICP).  It is intuitive to 
emphasize that patients with increased 
ICP should not push during the second 
stage of labor to avoid brainstem 
herniation. Our patient, though 
intermittently experiencing symptoms of 
increased ICP, was able to tolerate 
Valsalva maneuver (e.g. with bowel 
movements) during her antepartum stay 
and was hence permitted to push during 
labor.  
Of note, epidural anesthesia is 
considered a contraindication in this 
setting because neurofibromas may 
involve the spinal cord and nerve roots. 
However, reported cases have 
employed successful epidural analgesia 
after having ruled out spinal 
neurofibromas by CT scan, and this 
option can be considered on a case-by-
case basis.13,14 In our case, epidural 
analgesia was contraindicated due to 
spinal tumors seen on MRI.  
In conclusion, acoustic neuromas during 
pregnancy are very rare, but can be 
managed successfully with an 
interdisciplinary team approach tailored 
to the patient’s specific clinical 
presentation. 
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